Cargando…
MK-8776, a novel chk1 kinase inhibitor, radiosensitizes p53-defective human tumor cells
Radiotherapy is commonly used to treat a variety of solid tumors but improvements in the therapeutic ratio are sorely needed. The aim of this study was to assess the Chk1 kinase inhibitor, MK-8776, for its ability to radiosensitize human tumor cells. Cells derived from NSCLC and HNSCC cancers were t...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342109/ https://www.ncbi.nlm.nih.gov/pubmed/27690219 http://dx.doi.org/10.18632/oncotarget.12311 |